Skip to main content
CVSCVS Health CorporationSell5.5·$107.74+0.80%
SellModerate Confidence
Investment thesis

CVS Health has delivered four consecutive earnings beats with an average positive surprise near 17% and converts net income to free cash flow at a ratio of roughly 1.8 times. However, the stock has reached its near-term price target with zero headroom remaining and a reward-to-risk ratio at essentially zero, overall quality sits below the minimum threshold at 3.3 out of 10, and an active legal risk event has triggered a gate failure alongside a dividend safety warning.

Thesis pillars

  • Quality Below Minimum FloorDeteriorating
  • Consistent Earnings OutperformanceStable
  • Strong Free Cash Flow ConversionStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

CVS Health Corporation (CVS) Stock Analysis

Catalyst-Driven edge

SellGrowthModerate Confidence

Healthcare · Healthcare Plans

Sell if holding. Engine safety override at $107.74: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality.

CVS Health operates approximately 9,000 retail pharmacies, 1,000+ medical clinics, a PBM serving ~87 million plan members, and Aetna insurance serving ~37 million members across four segments. Revenue comes from pharmacy dispensing, PBM service fees, and health insurance... Read more

$107.74-6.3% A.UpsideScore 5.5/10#6 of 11 Healthcare Plans
QualityF-score6 / 9FCF yield3.78%
IncomeYield2.49%(5y avg 3.23%)Payout116.67%at-risk
Stop $102.76Target $107.80(resistance)A.R:R -1.0:1
Analyst target$112.19+4.1%26 analysts
$107.80our TP
$107.74price
$112.19mean
$79
$148

Sell if holding. Engine safety override at $107.74: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.

Passes 4/8 gates (positive momentum, clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-26
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Aug 5, 202611d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Target reached (-6.3% upside)
Quality below floor (3.3 < 4.0)

Key Metrics

P/E (TTM)47.3
P/E (Fwd)12.8
Mkt Cap$137.5B
EV/EBITDA13.2
Profit Mgn0.7%
ROE3.8%
Rev Growth6.1%
Beta0.60
Dividend2.49%
Rating analysts33

Quality Signals

Piotroski F6/9

Options Flow

P/C0.07bullish
IV49%normal

Concentration Risks(10-K Item 1A)

  • LOWCustomerU.S. federal government20%
    10-K Item 1: 'Health Care Benefits segment revenues from the federal government accounted for approximately 20% of the Company's consolidated total revenues in 2025'

Material Events(8-K, last 90d)

  • 2026-05-18Item 5.02LOW
    CVS Health 2026 Annual Meeting (May 14, 2026): stockholders approved the 2026 Incentive Compensation Plan, replacing the expiring 2017 plan. No officer departures or director elections reported in this item.
    SEC filing →
  • 2026-03-19Item 5.02LOW
    Board elected John E. Gallina (former CFO of Elevance Health) as director, effective March 19, 2026. Routine board addition; no officer departure cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Net Margin
0.4
Roe
1.3
Operating Margin
1.6
Roa
1.8
Current Ratio
3.5
Moat
4.2
Piotroski F
6.7
Fcf Quality
10.0
Excellent cash conversion: 177% FCF/NINo competitive moat

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
3.9
Quality Rank
4.1
Growth Rank
5.5
GatesA.R:R -1.0=NEGATIVEMomentum 4.6<5.5 (soft — BUY_NOW allowed but watch)Executive change: officer departure/appointmentEARNINGS PROXIMITY 11d<=14d (soft)Momentum 4.6>=4.5Insider activity: OKSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
69 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $101.15Resistance $110.00

Price Targets

$103
$108
A.Upside-6.3%
A.R:R-1.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-6.3% upside)
! Quality below floor (3.3 < 4.0)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-05 (11d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CVS stock a buy right now?

Sell if holding. Engine safety override at $107.74: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $102.76. Score 5.5/10, moderate confidence.

What is the CVS stock price target?

Take-profit target: $107.80 (-6.3% upside). Prior stop was $102.76. Stop-loss: $102.76.

What are the risks of investing in CVS?

Target reached (-6.3% upside); Quality below floor (3.3 < 4.0).

Is CVS overvalued or undervalued?

CVS Health Corporation trades at a P/E of 47.3 (forward 12.8). TrendMatrix value score: 6.8/10. Verdict: Sell.

What do analysts say about CVS?

33 analysts cover CVS with a consensus score of 4.1/5. Average price target: $112.

What does CVS Health Corporation do?CVS Health operates approximately 9,000 retail pharmacies, 1,000+ medical clinics, a PBM serving ~87 million plan...

CVS Health operates approximately 9,000 retail pharmacies, 1,000+ medical clinics, a PBM serving ~87 million plan members, and Aetna insurance serving ~37 million members across four segments. Revenue comes from pharmacy dispensing, PBM service fees, and health insurance premiums; federal government programs represented ~20% of consolidated 2025 revenues.

Related stocks: CI (The Cigna Group) · UNH (UnitedHealth Group Incorporated) · CNC (Centene Corporation) · ELV (Elevance Health, Inc.) · HUM (Humana Inc.)
Home Stocks CVS

Latest news

Latest News

Benzinga5d agoCONCERN
Benzinga3d agoFda Decision
Benzinga10d ago
Benzinga11d agoLegal
Benzinga11d agoLegal
Benzinga12d agoAnalyst
Benzinga13d agoAnalyst
Benzinga13d ago
Benzinga16d agoMerger Acquisition
Benzinga17d ago
Benzinga18d ago
Benzinga18d ago
Benzinga19d agoAnalyst
Benzinga22d ago
Benzinga33d agoLegal
Benzinga33d ago
Benzinga33d ago
Benzinga34d agoProduct
Benzinga38d ago
Benzinga45d agoLegal
Loading more...